Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
Cytometry Part B: Clinical Cytometry · 2025-05 · 108 (3) · 252-266
DOI: 10.1002/cyto.b.22202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 21.08.2024. Verfasst von Sara A Monaghan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Flow Cytometry. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
The Clinical and Laboratory Standards Institute (CLSI) H62— Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Clinical Pharmacology and Safety Sciences, Astra Zeneca, Gaithersburg, Maryland, USA.
- Department of Pathology, Cleveland Clinic Florida, Weston, Florida, USA.
- Department of Clinical Flow Cytometry, Quest Diagnostics, Lewisville, Texas, USA.
- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
- Labcorp, Geneva, Switzerland.
ORCID-Profile: Sara A Monaghan, Nina Rolf, Paul K Wallace, Horatiu Olteanu
Zitieren
APA
Monaghan, S. A., Eck, S., Bunting, S., Dong, X. X., Durso, R. J., Gonneau, C., Hays, A., Illingworth, A., League, S. C., Linskens, E., McCausland, M., McCloskey, T. W., Rolf, N., Shi, M., Wallace, P. K., Litwin, V., Kern, W., Deeb, G., Nash, V., & Olteanu, H. (2025). Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines. Cytometry Part B: Clinical Cytometry, 108(3), 252-266. https://doi.org/10.1002/cyto.b.22202
Vancouver
Monaghan SA, Eck S, Bunting S, Dong XX, Durso RJ, Gonneau C, et al. Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines. Cytometry Part B: Clinical Cytometry. 2025;108(3):252-266. doi:10.1002/cyto.b.22202
BibTeX
@article{Monaghan2025,
author = {Monaghan, Sara A and Eck, Steven and Bunting, Silvia and Dong, Xiangyang X and Durso, Robert J and Gonneau, Christele and Hays, Amanda and Illingworth, Andrea and League, Stacy C and Linskens, Eleni and McCausland, Megan and McCloskey, Thomas W and Rolf, Nina and Shi, Min and Wallace, Paul K and Litwin, Virginia and Kern, Wolfgang and Deeb, George and Nash, Veronica and Olteanu, Horatiu},
title = {Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2025},
volume = {108},
number = {3},
pages = {252--266},
doi = {10.1002/cyto.b.22202}
}
EUVIMED